Clinical trial NCT06904755: Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure
Official title: Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Liver Failure
Lead sponsor: Zhujiang Hospital
Sponsor class: OTHER
First posted: 2025-04-01
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if mesenchymal stem cells in blood purification works to treat liver failure in adults. It will also learn about the safety and effectiveness of mesenchymal stem cells in blood purification. The main questions it aims to answer are:1.Does mesenchymal stem cells in blood purification improve the condition of patients with liver failure? 2.What medical problems do participants have when taking mesenchymal stem cells in blood purification? Participants will receive routine medical treatment and blood purification treatment with mesenchymal stem cells.These cells work outside the body and do not enter the body. We will: 1.Collect samples from participants such as blood, Urine and feces. 2.record post-treatment outcomes such as survival rate at 4 weeks after treatment, conversion rate to liver transplantation, Inflammatory, survival rate at 7days, 14days, 8 weeks and 12 weeks after treatment, and liver disease indicators(prothrombin time activity percentage, lactic aicd, blood ammonia, α-fetoprotein, ferritin).


Eligibility criteria: Inclusion Criteria:

1. Age range from 18 to 65 years old;
2. Patients with acute liver failure in the early and intermediate stages caused by various reasons;
3. Total bilirubin (TBil) ≥ 171μmol/L or an increase of ≥ 17.1μmol/L per day;
4. Prothrombin activity (PTA) between 20% and 40% (or INR between 1.5 and 2.6);
5. No hepatic encephalopathy or encephalopathy below grade II (including grade II);
6. Elevated inflammatory markers (IL-6 / TNF-α / CRP, etc.);
7. The subjects are able to communicate well with the researchers and can complete the study in accordance with the study regulations;
8. The subjects must be informed of this study and voluntarily sign a written informed consent form before the experiment.

Exclusion Criteria:

1. Patients with severe active bleeding or diffuse intravascular coagulation;
2. Patients with a high degree of allergy to blood products or drugs used during treatment, such as plasma, heparin, and protamine;
3. Patients with circulatory failure;
4. Patients with a MELD score \> 30;
5. Patients with other severe heart diseases, lung diseases, blood diseases, autoimmune diseases, or diabetes;
6. Subjects who may be unable to complete this study for other reasons or who the researchers believe should not be included.

Primary outcomes:
measure: Survival rate on day 28 after treatment
timeFrame: From enrollment to day 28 after treatment.
Secondary outcomes:
measure: conversion rate to liver transplantation
timeFrame: From enrollment to day 28, 56, 84 after treatment.
measure: Interleukin-6(IL-6)
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: Survival rate on day 7, 14, 56, 84 after treatment
timeFrame: From enrollment to day 7, 14, 56, 84 after treatment.
measure: lactic aicd
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: Model for End-Stage Liver Disease score
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: Chinese group on the study of severe hepatitis B-acute-on-chronic liver failure score
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: tumor necrosis factor α (TNF-α)
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: C-reactive protein (CRP)
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: blood ammonia
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: Alpha-fetoprotein (AFP)
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: ferritin
timeFrame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
measure: Incidence rate of adverse events (AE incidence rate)
timeFrame: Throughout the entire course of MSC-based blood purification therapy.
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhujiang hospital
state: Guangdong
Study officials:
References: